Product Details
| Product Name:
AUDA |
CAS No.:
479413-70-2 |
| Purity:
99.50% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | AUDA |
| Description | AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively) |
| Cell Research | Cell Line:Vascular smooth muscle cell (VSMC).Concentration:0.3, 1, 3, 10 μg/mL. Incubation Time:48 hours[1] |
| Animal Research | AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels.Animal Model:Male (wild-type). C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g).Dosage:10 mg/kg.Administration:i.p.; 14 days[2] |
| In vitro | AUDA significantly inhibited PDGF-induced rat VSMC proliferation, which coincided with Pin1 suppression and heme oxygenase-1 (HO-1) upregulation.?However, exogenous 8,9-EET, 11,12-EET, and 14,15-EET treatments did not alter Pin1 or HO-1 levels and had little effect on the proliferation of rat VSMCs.?On the other hand, AUDA enhanced the PDGF-stimulated cell migration of rat VSMCs.?Furthermore, AUDA-induced activation of cyclooxygenase-2 (COX-2) and subsequent thromboxane A2 (TXA?) production were required for the enhanced migration[1]. |
| In vivo | AUDA increased the proliferation, migration, adhesion and tube formation ability of HCAECs in a dose-dependent manner.?Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1β and TNF-α, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (76.42 mM), Sonication is recommended.
|
| Keywords | VSMC | soluble | sEH | Inhibitor | inhibit | hydrolase | EpoxideHydrolase | Epoxide Hydrolase | epoxide | AUDA | anti-inflammatory | activity |
| Inhibitors Related | 1,3-Diphenylurea | Valpromide | VU534 | PAL-4 | N,N'-Dicyclohexylurea | Diflapolin | (Rac)-EC5026 | CAY10640 | sEH inhibitor-3 | GSK2256294A | Dual FAAH/sEH-IN-1 | 1,3-Dibenzylurea |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1784701-61-6
$2520.00
-
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States